108 related articles for article (PubMed ID: 6456216)
21. Demonstration of granulocytic proteases in plasma of patients with acute leukemia and septicemia with coagulation defects.
Egbring R; Schmidt W; Fuchs G; Havemann K
Blood; 1977 Feb; 49(2):219-31. PubMed ID: 299817
[TBL] [Abstract][Full Text] [Related]
22. The cleavage of beta-chain in bovine fibrinogen DH fragment (95 kDa) leads to a significant increase in its anticlotting activity.
Medved LV; Platonova TN; Litvinovich SV; Lukinova NI
FEBS Lett; 1988 May; 232(1):56-60. PubMed ID: 2966748
[TBL] [Abstract][Full Text] [Related]
23. Granulocyte-platelet interactions and platelet fibrinogen receptor exposure.
Kornecki E; Ehrlich YH; Egbring R; Gramse M; Seitz R; Eckardt A; Lukasiewicz H; Niewiarowski S
Am J Physiol; 1988 Sep; 255(3 Pt 2):H651-8. PubMed ID: 3414826
[TBL] [Abstract][Full Text] [Related]
24. Granulocyte lysosomal factors and plasma elastase in uremia: a potential factor of catabolism.
Heidland A; Hörl WH; Heller N; Heine H; Neumann S; Schaefer RM; Heidbreder E
Klin Wochenschr; 1984 Mar; 62(5):218-24. PubMed ID: 6201647
[TBL] [Abstract][Full Text] [Related]
25. Evidence of fibrinogen breakdown by leukocyte enzymes in a patient with acute promyelocytic leukemia.
Sterrenberg L; Haak HL; Brommer EJ; Nieuwenhuizen W
Haemostasis; 1985; 15(2):126-33. PubMed ID: 3859461
[TBL] [Abstract][Full Text] [Related]
26. Immunochemical discrimination of leukocyte elastase from plasmic degradation products of fibrinogen.
Plow EF; Gramse M; Havemann K
J Lab Clin Med; 1983 Dec; 102(6):858-69. PubMed ID: 6227673
[TBL] [Abstract][Full Text] [Related]
27. The fibrinogenolytic activity of purified tryptase from human lung mast cells.
Schwartz LB; Bradford TR; Littman BH; Wintroub BU
J Immunol; 1985 Oct; 135(4):2762-7. PubMed ID: 3161948
[TBL] [Abstract][Full Text] [Related]
28. Fibrinogen Haifa: fibrinogen variant with absence of protective effect of calcium on plasmin degradation of gamma chains.
Soria J; Soria C; Samama M; Tabori S; Kehl M; Henschen A; Nieuwenhuizen W; Rimon A; Tatarski I
Thromb Haemost; 1987 Jun; 57(3):310-3. PubMed ID: 2958955
[TBL] [Abstract][Full Text] [Related]
29. Calcium modulates plasmin cleavage of the fibrinogen D fragment gamma chain N-terminus: mapping of monoclonal antibody J88B to a plasmin sensitive domain of the gamma chain.
Odrljin TM; Rybarczyk BJ; Francis CW; Lawrence SO; Hamaguchi M; Simpson-Haidaris PJ
Biochim Biophys Acta; 1996 Nov; 1298(1):69-77. PubMed ID: 8948490
[TBL] [Abstract][Full Text] [Related]
30. The digestion of the oxidized B chain of insulin by human neutrophile proteases: elastase and chymotrypsin-like protease.
Levy H; Feinstein G
Biochim Biophys Acta; 1979 Mar; 567(1):35-42. PubMed ID: 454627
[TBL] [Abstract][Full Text] [Related]
31. Isolation of elastase-like and chymotrypsin-like neutral proteases from human granulocytes.
Schmidt W; Havemann K
Hoppe Seylers Z Physiol Chem; 1974 Sep; 355(9):1077-82. PubMed ID: 4461651
[No Abstract] [Full Text] [Related]
32. Neutral proteases of human granulocytes. III. Interaction between human granulocyte elastase and plasma protease inhibitors.
Ohlsson K; Olsson I
Scand J Clin Lab Invest; 1974 Dec; 34(4):349-55. PubMed ID: 4142517
[No Abstract] [Full Text] [Related]
33. Alpha 2-plasmin inhibitor inactivation by human granulocyte elastase.
Gramse M; Egbring R; Havemann K
Hoppe Seylers Z Physiol Chem; 1984 Jan; 365(1):19-26. PubMed ID: 6562066
[TBL] [Abstract][Full Text] [Related]
34. Factors influencing the structure of terminal plasmin degradation products of human fibrinogen and fibrin.
Nieuwenhuizen W; Vermond A; Haverkate F
Biochim Biophys Acta; 1981 Feb; 667(2):321-7. PubMed ID: 6452172
[TBL] [Abstract][Full Text] [Related]
35. Human tumor cell urokinase-type plasminogen activator (uPA): degradation of the proenzyme form (pro-uPA) by granulocyte elastase prevents subsequent activation by plasmin.
Schmitt M; Kanayama N; Jänicke F; Hafter R; Graeff H
Adv Exp Med Biol; 1991; 297():111-28. PubMed ID: 1837419
[TBL] [Abstract][Full Text] [Related]
36. Fibrinogen St. Gallen I (gamma 292 Gly--> Val): evidence for structural alterations causing defective polymerization and fibrinogenolysis.
Stucki B; Schmutz P; Schmid L; Haeberli A; Lämmle B; Furlan M
Thromb Haemost; 1999 Feb; 81(2):268-74. PubMed ID: 10064005
[TBL] [Abstract][Full Text] [Related]
37. [The role of DL and DH degradation products in the reactions of the plasmin hydrolysis of fibrinogen and fibrin].
Rozenfel'd MA; Leonova VB; Khavkina LS
Izv Akad Nauk SSSR Biol; 1991; (3):334-42. PubMed ID: 1835465
[TBL] [Abstract][Full Text] [Related]
38. A fibrinogen fragment D (D intermediate) with calcium binding but without anticlotting properties.
Nieuwenhuizen W; Voskuilen M; Vermond A; Haverkate F; Hermans J
Biochim Biophys Acta; 1982 Oct; 707(2):190-2. PubMed ID: 7138883
[TBL] [Abstract][Full Text] [Related]
39. Detection of granulocyte elastase specific IgG split products in rheumatoid synovial fluid.
Eckle I; Kolb G; Neurath F; Havemann K
Adv Exp Med Biol; 1988; 240():531-4. PubMed ID: 3245504
[TBL] [Abstract][Full Text] [Related]
40. The role of the lysine binding sites of human plasmin in the hydrolysis of human fibrinogen.
Morris JP; Castellino FJ
Biochim Biophys Acta; 1983 Apr; 744(1):99-104. PubMed ID: 6219709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
